AngioDynamics gets FDA OK for prostate cancer study

06/20/2013 |

AngioDynamics has received investigational device exemption approval from the FDA to conduct a clinical study of its NanoKnife technology, which uses precise ablation to treat patients with localized prostate cancer. The trial will enroll 200 patients from six clinical sites in Europe.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC